|FedDev Ontario supports process development
PlantForm is partnering with Conestoga College to advance our process development, with the support of the Federal Economic Development Agency for Southern Ontario’s (FedDev Ontario) Applied Research and Commercialization (ARC) Initiative.
Through Conestoga, FedDev Ontario will contribute $48,647 along with an in-kind contribution of $31,000 from PlantForm for the completion of the project. The objective of the project is to optimize our methods and techniques related to antibody expression and purification for each step of the process.
FedDev Ontario’s funding through the Applied Research and Commercialization Initiative aims to move promising new products to the marketplace more quickly.
Animal studies under way
Animal safety and toxicology studies are now under way to determine how PlantForm’s subsequent entry biologic (SEB) trastuzumab performs in a mouse model. In vitro studies, published in the Journal of Agricultural and Food Chemistry, have already shown that our SEB trastuzumab effectively inhibits the growth of HER2-positive cancer cells and has the same activity as the commercial antibody (Herceptin).
Doug Cossar named Director Development
PlantForm is pleased to announce the appointment of Dr. Doug Cossar as Director Development. He will be responsible for process scale-up and clinical product development activities. Dr. Cossar also serves on PlantForm’s Scientific Advisory Board, and has recent experience as Principal Investigator (Biotechnology) for the Structural Genomics Consortium at the University of Toronto.
PlantForm co-founder and Scientific Advisory Board member Dr. Kenneth Hughes was interviewed for a Genetic Engineering & Biotechnology News story on biosimilar market prospects and perils. Read Biosimilars Proceed With Caution From the Starting Gate.
Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter and LinkedIn:
Two PlantForm patents have now advanced to the National Phase Entry stage: Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments
and Anti-Cobra Toxin Antibody Fragments.
PlantForm presented its business case at the BIO International Convention
in Washington, DC, June 27-30. PlantForm will also be attending:
Don Stewart, PhD
President & CEO
Ron Hosking, CA
Chief Financial Officer
Chris Hall, PhD
Chief Scientific Officer